A study published in The Lancet Infectious Diseases reports that a team of European researchers developed a chlamydia vaccine that was proven safe and effective in an early trial.Key Takeaways:
- Chlamydia is the most common bacterial sexually transmitted infection (STI) globally. Although most cases show no symptoms, 1 in 6 cases progresses to pelvic inflammatory disease, which can lead to infertility, pelvic pain, and ectopic pregnancy.
- No vaccine has been developed for chlamydia before. Chlamydia is currently treated with antibiotics and screened for with STI testing.
- This trial, which showed a desired immune response against chlamydia bacteria in 35 healthy participants, is very promising.
- However, further trials are needed before a vaccine can be deemed successful, including testing the vaccine’s success in people who already have chlamydia exposure. Vaccines commonly spend about 10-20 years in development, so this vaccine may not be commercially available any time soon.
Read the original article here.